FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.
REUTERS/Mike Segar(Reuters) -Eli Lilly and Co said on Thursday it had received a subpoena from the U.S. Department of Justice related to its New Jersey plant that makes its COVID-19 treatment, bamlanivimab.
The subpoena requested certain documents relating to its site in Branchburg, New Jersey, and the company is cooperating with the investigation, Eli Lilly said.
Eli Lilly is also under pressure due to quality control, production and regulatory issues at its Indianapolis plant, which bottles bamlanivimab, among other drugs.
Last year, Eli Lilly hired an independent consultant to review the New Jersey plant after receiving an Official Action Indicated notice from the U.S. health regulator.
Eli Lilly, Mike Segar, drugmaker
Company, REUTERS, U.S . Department of Justice, Reuters, U.S . Food
Branchburg , New Jersey, New Jersey, U.S, Indianapolis, Jersey